Other Biomarkers in UC

Biomarkers in urine or exfoliated cells isolated from urine may be used to diagnose and monitor recurrence of UC.1 FDA-approved tests are available for detecting some of these biomarkers.1,2

 

NCCN recommendations

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation

 

Only monitor for disease recurrence using FDA-approved urinary biomarkers for either3:

 

Chromosomal alterations by fluorescence in situ hybridization

NMP22 


According to NCCN Guidelines®, testing for
urinary biomarkers to detect cancer during
follow-up is optional.3


According to NCCN Guidelines®, testing for urinary biomarkers to detect cancer during follow-up is optional.3

FDA, Food and Drug Administration; NCCN, National Comprehensive Cancer Network; NMP, nuclear matrix protein; UC, urothelial carcinoma.

 

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 

References: 1. Kamat AM et al. Eur Urol. 2013;63(1):4-15. 2. Hall MC et al. J Urol. 2007;178(6):‍2‍314-2330. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V5.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed September 27, 2018. To view the most recent and complete version of the guidelines, go online to NCCN.org.

Emerging Prognostic Markers

 

Selected emerging prognostic biomarkers for UC1,2

Selected emerging prognostic biomarkers for UC1,2

  Biomarker Outcome
  • Cell cycle
  • Tumor protein p53
  • Cyclin-dependent kinase inhibitors p21, p27
  • Retinoblastoma-like protein 1 (pRb)
  • Proliferation index (Ki-67/MiB1)
  • Cyclin E1
  • DFS, CSS
  • DFS, CSS 
  • DFS, CSS 
  • DFS, CSS
  • DFS, CSS
  • Apoptosis
  • Fas
  • Caspase-3
  • B-cell lymphoma  (Bcl)-2
  • Survivin
  • CSS
  • DFS, CSS
  • DFS, CSS
  • DFS, CSS
  • Angiogenesis
  • Microvessel density
  • Thrombospondin-1
  • DFS, CSS
  • DSS, CSS
  • Signaling proteins
  • EGFR
  • DFS, CSS
  • Hormone receptors
  • Estrogen receptor
  • HER2
  • DFS
  • DFS, CSS
  • Cell cycle
Biomarkers Outcome
  • Tumor protein p53
  • DFS, CSS
  • Cyclin-dependent kinase inhibitors p21, p27
  • DFS, CSS
  • Retinoblastoma-like protein 1 (pRb)
  • DFS, CSS
  • Proliferation index  (Ki-67/MiB1)
  • DFS, CSS
  • Cyclin E1
  • DFS, CSS
  • Apoptosis
Biomarkers Outcome
  • Fas
  • CSS
  • Caspase-3
  • DFS, CSS
  • B-cell lymphoma (Bcl)-2
  • DFS, CSS
  • Survivin
  • DFS, CSS
  • Angiogenesis
Biomarkers Outcome
  • Microvessel density
  • DFS, CSS
  • Thrombospondin-1
  • DSS, CSS
  • Signaling proteins
Biomarkers Outcome
  • EGFR
  • DFS, CSS
  • Hormone receptors
Biomarkers Outcome
  • Estrogen receptor
  • DFS
  • HER2
  • DFS, CSS

 

CSS, cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; UC, urothelial carcinoma.

 

References: 1. Kamat AM et al. Eur Urol. 2013;63(1):4-15. 2. Hall MC et al. J Urol. 2007;178(6):‍2314-2330.